Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.

Autor: Samanta A; Cullen Eye Institute, Baylor College of Medicine, Houston, TX., Bordbar DD, Weng CY, Chancellor JR
Jazyk: angličtina
Zdroj: International ophthalmology clinics [Int Ophthalmol Clin] 2025 Jan 01; Vol. 65 (1), pp. 23-26. Date of Electronic Publication: 2024 Dec 23.
DOI: 10.1097/IIO.0000000000000541
Abstrakt: Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of drugs, most well known by the third-generation once-weekly subcutaneous semaglutide, that act on the incretin pathway of metabolic, hormonal signaling to modulate pancreatic insulin release, gastric emptying, energy intake, and subjective feelings of satiety. This class of drugs' efficacy and safety in the treatment of type 2 diabetes and obesity have been demonstrated across multiple large randomized controlled trials. These data have propelled GLP-1 receptor agonists to ubiquity in diabetic management and weight loss therapy, leading them to be frequently encountered in ophthalmic practice. The effect of GLP-1 receptor agonists like semaglutide on diabetic retinopathy (DR) is at this point unclear; some studies indicate a worsening of DR with the initiation of GLP-1 agonists, especially semaglutide. Overall, the macrovascular reduction of cardiovascular and stroke risks from GLP-1 receptor agonists should be prioritized over the potential microvascular progression of DR, as long as the patient is regularly followed by ophthalmology.
Competing Interests: C.Y.W. discloses the following relationships outside of the submitted work: Allergan/AbbVie, Alcon, Apellis Pharmaceuticals, Alimera Sciences, DORC, Novartis, Genentech, Regeneron, REGENXBIO, Astellas/Iveric Bio, EyePoint (consultant); DRCR Retina Network, Alimera Sciences, AGTC (research); Springer Publishers (royalties). The remaining authors declare that they have no conflicts of interest to disclose.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze: MEDLINE